INmune Bio Inc. (NASDAQ: INMB)
$4.9100
+0.1500 ( +3.15% ) 35.3K
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Market Data
Open
$4.9100
Previous close
$4.7600
Volume
35.3K
Market cap
$106.46M
Day range
$4.7520 - $4.9160
52 week range
$4.4500 - $14.7400
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 14 | Nov 14, 2024 |
| 8-k | 8K-related | 41 | Nov 13, 2024 |
| 8-k | 8K-related | 15 | Nov 01, 2024 |
| 10-q | Quarterly Reports | 62 | Oct 31, 2024 |
| 8-k | 8K-related | 14 | Oct 28, 2024 |
| 8-k | 8K-related | 14 | Oct 25, 2024 |
| 8-k | 8K-related | 15 | Oct 24, 2024 |
| 8-k | 8K-related | 15 | Oct 11, 2024 |
| 4 | Insider transactions | 1 | Sep 30, 2024 |
| 8-k | 8K-related | 15 | Sep 26, 2024 |